Home/Pipeline/AN3025

AN3025

Advanced Solid Tumors

PreclinicalActive

Key Facts

Indication

Advanced Solid Tumors

Phase

Preclinical

Status

Active

Company

Adlai Nortye

About Adlai Nortye

Adlai Nortye is a Cayman Islands-incorporated, China and US-based biotech company dedicated to discovering and developing novel anti-cancer treatments. Its strategy centers on advancing buparlisib, a drug with a history in other cancers, into a new pivotal indication (HNSCC) while building a broader pipeline targeting the tumor microenvironment. The company went public on the NASDAQ in 2023, raising capital to fund its late-stage clinical development and expand its research efforts.

View full company profile

Therapeutic Areas

Oncology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
SHR-1701	Jiangsu Hengrui Medicine	Phase 1	Active
BAY 1895344	Bayer	Phase 1	Active
HS-10342	Hansoh Pharma	Phase 1/2	Active
ANKTIVA® + M-ceNK	ImmunityBio	Phase 1	Active
DFTX-101	Definium Therapeutics	Phase 1/2	Active
REC-617	Recursion Pharmaceuticals	Phase 1/2	Active
ZW220	Zymeworks	Preclinical	Active
NX-1607	Nurix Therapeutics	Phase 1a	Active
IMA402 (TCR Bispecific)	Immatics	Phase 1	Active
IMA403 (TCR Bispecific)	Immatics	Pre-clinical	Research
BCA101	Bicara Therapeutics	Phase 1	Completed
AN4005	Adlai Nortye	Preclinical	IND-enabling